-N-ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-[2-methyl-2-(3-thienylmethoxy)propyloxy]benzylamine hydrochloride), a squalene epoxidase inhibitor, on lipid metabolism were compared with those of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, in hamsters. Drugs were given for 10 d either as a diet mixture or as a bolus oral gavage, and similar results were obtained with each type of administration. FR194738 (0.01-0.32% as a diet mixture; 10-100 mg/kg as an oral gavage) dose-dependently decreased serum total cholesterol, non high density lipoprotein (HDL) cholesterol, HDL cholesterol and triglyceride levels, and the changes in serum parameters were similar. Pravastatin (0.01-0.32% as a diet mixture; 1-100 mg/kg as an oral gavage) increased serum cholesterol levels, and dose-dependently decreased serum triglyceride levels. Although oral gavage of FR194738 at 32 mg/kg and pravastatin at 3.2 and 10 mg/kg increased hepatic HMG-CoA reductase activity, the degree of the changes was far greater with the latter than the former drug. FR194738 slightly increased hepatic cholesterol content at 32 mg/kg, whereas pravastatin dose-dependently increased hepatic cholesterol content until it leveled off at 32 and 100 mg/kg. It is concluded that inhibition of squalene epoxidase and HMG-CoA reductase triggers both hypercholesterolemic (hepatic cholesterol synthesis) and hypocholesterolemic (hepatic cholesterol uptake) mechanisms. FR194738 appears to induce a greater enhancement of the latter rather than the former, whereas pravastatin has a greater effect on the former.
It has been postulated that hypercholesterolemia is a major risk factor for the development of atherosclerotic vascular diseases and ischemic heart disease. 1) Clinical trials have demonstrated that lowering plasma cholesterol by diet or drug intervention leads to benefits for hypercholesterolemic patients. 2, 3) One of the most effective ways of reducing circulating cholesterol levels is to inhibit endogenous cholesterol synthesis in the liver.
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyzes the rate-determining step of cholesterol biosynthesis, 4) and it has been demonstrated that inhibitors of HMG-CoA reductase effectively lower plasma cholesterol levels in humans. 5) On the other hand, inhibition of this enzyme leads to a concomitant reduction of non-sterol products such as farnesol, ubiquinone, dolichol and isoprenylated protein, 6, 7) some of which are known to be essential for multivalent feedback regulation of HMG-CoA reductase. 8) Thus, the reduction of non-sterol products by HMG-CoA reductase inhibitors may trigger induction of HMG-CoA reductase itself, and may limit efficacy or even abolish the cholesterol lowering effects, as evidenced in rats. 9) Squalene epoxidase is a microsomal enzyme that catalyzes conversion of squalene to 2,3-oxidosqualene. 10) This enzyme is located downstream in the cholesterol synthesis pathway, past the branch points for the biosynthesis of the non-sterol products mentioned above. Inhibition of squalene epoxidase could therefore prevent the blocking of their production. We recently demonstrated that a squalene epoxidase inhibitor, FR194738 ((E)-N-ethyl-N-(6,6-dimethyl-2-hepten-4-ynyl)-3-[2-methyl-2-(3-thienylmethoxy)propyloxy]benzylamine hydrochloride), 11) causes reduced induction of HMG-CoA reductase activity in HepG2 cells, compared with inhibitors of HMG-CoA reductase and decreases serum cholesterol levels in dogs and hamsters. 12) In this study, we examined the effects of FR194738 on serum lipid levels and hepatic cholesterol metabolism in hamsters and compared the results with those of pravastatin, an inhibitor of HMG-CoA reductase.
MATERIALS AND METHODS

Materials
FR194738 was synthesized at Fujisawa Pharmaceutical Co., Ltd. (Osaka, Japan). Pravastatin was purchased as Mevalotin tablets and extracted. [4, 8, 12, 13, 17, H]-squalene (865.8 GBq/mmol, NET-645) and [3- 14 C]-HMG-CoA (2.1083 GBq/mmol, NEC-642) were purchased from DuPont NEN (Boston, MA, U.S.A.).
Animals Six-week-old male golden Syrian hamsters (70-110 g) were purchased from SLC (Hamamatsu, Japan) at least 1 week before the experiments. Animals were housed in a temperature-and humidity-controlled environment under a 12 : 12 h light/dark cycle with light on at 7:00 A.M. Animals were allowed free access to food and water ad libitum.
Preparation of Microsomes Microsomes for in vitro enzyme assay were prepared from livers of male golden syrian hamsters which were given 2% cholestyramine in diet for 10 d to increase HMG-CoA reductase activity 13) and squalene epoxidase activity. 14) Livers were minced and homogenized in 3 volumes of buffer containing 0.1 M sucrose, 0.05 M KCl, 0.04 M KH 2 PO 4 , 0.03 M EDTA, and 1 mM dithiothreitol at pH 7.2, and the same buffer was used throughout the preparation procedure described. The homogenate was centrifuged at 1000ϫg for 10 min, and the supernatant was centrifuged at 10000ϫg for 20 min. The supernatant was centrifuged at 100000ϫg for 60 min. The microsomal pellet was suspended and centrifuged again at 100000ϫg for 60 min. The resulting microsomal pellet was resuspended and stored at Ϫ80°C until use. All of the above operations were carried out at 4°C.
Squalene Epoxidase Assay Squalene epoxidase activity was determined according to the method of Tai and Bloch 15) with some modifications. Microsomes were solubilized with 2% Triton X-100 in 0.1 M Tris-HCl buffer, pH 7.5, for 20 min at 4°C. 16) The reaction mixture containing 2 mg/ml microsomal protein, 0.1 M Tris-HCl buffer, pH 7.5, 1 mM EDTA, 1 mM NADPH, 0.1 mM FAD, 0.3 mM AMO-1618, 0.27% Triton X-100, and 8 mM [
3 H]squalene (3.7 kBq) dispersed in 0.075% Tween 80 was incubated for 30 min at 37°C at a final volume of 0.3 ml. The reaction was stopped by the addition of 0.3 ml of 10% ethanolic KOH. After incubation for 60 min at 75°C, non-saponifiable materials were extracted twice with petroleum ether. The extracts were evaporated under a nitrogen stream. The residue was taken up in a small volume of diethylether and spotted on a silica gel TLC plate, which was then developed in benzene/ethyl acetate (99.5 : 0.5, v/v). The radioactivity of the band corresponding to authentic 2,3-oxidosqualene was counted by digital autoradiography (Berthord, Tokyo, Japan).
HMG-CoA Reductase Assay HMG-CoA reductase activity was determined according to the method of Brown et al. 17) with some modifications. Microsomes were incubated for 60 min at 37°C in a final volume of 50 ml containing 0.1 M potassium phosphate, pH 7.5, 20 mM glucose-6-phosphate, 2.5 mM NADPH, 20 unit/ml glucose-6-phosphate dehydrogenase, 4 mM dithiothreitol, and 35 mM [ Animal Treatment Diet Mixture: Drugs were administered as a diet mixture for 10 d. Blood samples were collected via heart puncture under ether anesthesia and serum was prepared by centrifugation. The dose of 0.32% in diet corresponds to 127 and 116 mg/kg/d for FR194738 and pravastatin, respectively, calculated from body weight and food intake.
Repeat Administration: Drugs were dissolved or suspended in 0.5% methylcellulose (w/v) and were administered to hamsters by oral gavage once daily for 10 d. Hamsters in the control group received the vehicle (0.5% methylcellulose) alone. Sixteen hours after the last dosage, blood samples were collected via heart puncture under ether anesthesia and serum was prepared by centrifugation. Livers were excised under ether anesthesia.
Determination of Serum Lipids and Other Parameters Serum cholesterol and triglyceride were determined enzymatically with kits obtained from Wako (Osaka, Japan) using a TBA-80FR auto-analyzer (Toshiba, Tokyo, Japan). High density lipoprotein (HDL) cholesterol was determined similarly after removal of non HDL cholesterol through magnesium phosphotungstate precipitation (Wako). Non HDL cholesterol was calculated as the difference between serum and HDL cholesterol. Transaminases (GOT, GPT) and total bilirubin in serum were determined with kits obtained from Wako using a TBA-80FR auto-analyzer.
Determination of Liver Lipids Neutral lipids were extracted from liver samples with chloroform/methanol (2 : 1, v/v).
18) The extract was evaporated to dryness and the lipids were dissolved in a minimal volume of isopropanol. Total cholesterol and free cholesterol were determined enzymatically using assay kits (Wako). Cholesteryl ester was calculated as the difference between total and free cholesterol.
Determination of HMG-CoA Reductase Activity of Liver from Drug-Treated Hamsters Microsomes were prepared from the liver of hamsters treated with drugs as described above. In the preparation, microsomal pellets were washed once to remove residual pravastatin and further washing did not increase HMG-CoA reductase activity. HMGCoA reductase activity was measured as described in the presence of 1 mg protein/ml, in which the inhibitory effect of pravastatin remaining in the preparation was overcome by dilution. HMG-CoA reductase activity is presented as picomoles of mevalonate formed per milligram of microsomal protein per minute.
Determination of Microsomal Protein Concentration Protein concentrations were determined by the method of Bradford, 19) using bovine g-globulin as a standard. Statistical Analysis Results are presented as meanϮ S.E.M. For in vivo studies, drug-treatment values were compared with the vehicle-treatment control values using Dunnett's multiple comparison test. pϽ0.05 was considered to be significant.
RESULTS
In Vitro Assays FR194738 inhibited hamster liver microsomal squalene epoxidase activity in a concentration-dependent manner with an IC 50 value of 14 nM ( Fig. 1 ). In contrast, pravastatin essentially had no effect on this enzyme activity (106% of control at 10 mM).
Pravastatin inhibited hamster liver microsomal HMG-CoA reductase activity in a concentration-dependent manner with an IC 50 value of 5.1 nM (Fig. 2) . In contrast, FR194738 had no effect on the enzyme activity (102% of control at 10 mM).
Effects of FR194738 and Pravastatin in Diet on Serum Lipid Levels in Hamsters Serum lipid levels in hamsters after treatment with FR194738 and pravastatin as a diet mixture for 10 d are shown in Table 1 . FR194738 (0.01-0.32%) dose-dependently reduced serum levels of total, non HDL and HDL cholesterol. The changes of all parameters were similar; total cholesterol, non HDL cholesterol and HDL Hamster liver microsomes were incubated with FR194738 and 8 mM [
3 H]squalene. After 30 min incubation, the reaction was stopped by addition of 10% ethanolic KOH. Lipids were extracted with petroleum ether and separated by TLC, and radioactivity of [cholesterol levels were reduced by 14, 15 and 13%, respectively, at 0.1% in diet, while they were reduced by 19, 16 and 26%, respectively, at 0.32% in diet. Serum triglyceride levels were also reduced though the changes did not reach statistical significance. The reduction was 44 and 53% at 0.1 and 0.32% in diet, respectively.
Pravastatin increased serum total cholesterol, non HDL cholesterol and HDL cholesterol levels. The maximal and statistically significant increase in total cholesterol (29%) and non HDL cholesterol (25%) was obtained at 0.032% in diet, whereas that in HDL cholesterol (89%) was obtained at 0.1% in diet. On the other hand, pravastatin dose-dependently lowered serum triglyceride levels with maximum effect at 0.1% in diet.
Safety Parameters in Hamsters Treated with FR194738 and Pravastatin in Diet Body weight and serum parameters in hamsters after treatment with FR194738 and pravastatin as a diet mixture for 10 d are shown in Table 2 . FR194738 caused reduction in body weight at 0.1 and 0.32% in diet. There was no increase in serum transaminases and total bilirubin up to 0.32% in diet. Pravastatin caused dosedependent reduction in body weight at 0.032-0.32% in diet and increased serum GPT and total bilirubin at 0.1 and 0.32% in diet.
Effects of Daily Administration of FR194738 and Pravastatin on Serum Lipid Levels in Hamsters Serum lipid levels in hamsters after daily administration of FR194738 and pravastatin for 10 d are shown in Table 3 . FR194738 reduced the serum levels of total, non HDL and HDL cholesterol, and triglyceride. The changes were similar for all parameters, although those for non HDL cholesterol and triglyceride did not reach statistical significance. The total cholesterol, non HDL cholesterol, HDL cholesterol and triglyceride levels were reduced by 15, 11, 23 and 24%, respectively, at 100 mg/kg.
Pravastatin increased serum total cholesterol and HDL cholesterol levels. The maximal and statistically significant change in the total cholesterol (40%) was obtained at 3.2 mg/kg, whereas that in HDL cholesterol (77%) was obtained at 10 mg/kg. On the other hand, pravastatin dose-dependently lowered serum triglyceride levels with maximal effect at 32 mg/kg. Safety Parameters in Hamsters after Daily Administration of FR194738 and Pravastatin Body weight and serum parameters in hamsters after daily administration of FR194738 and pravastatin are shown in Table 4 . FR194738 was well tolerated up to 100 mg/kg. There was no significant change in body weight development and no increase in serum transaminases and total bilirubin. Pravastatin caused dose-dependent reduction in body weight, and pravastatin at 100 mg/kg was lethal. Pravastatin at doses from 32 mg/kg caused dose-dependent increases in serum transaminases and total bilirubin.
Liver Weight and Hepatic HMG-CoA Reductase Activity in Hamsters Treated with FR194738 and Pravastatin Liver weight and hepatic HMG-CoA reductase activity in hamsters after daily administration of FR194738 and pravastatin for 10 d are shown in Fig. 3 . FR194738 and pravastatin dose-dependently decreased liver weight (Figs. 3A, C) . The changes with pravastatin were statistically significant, while those with FR194738 were not significant. Treatment of hamsters with FR194738 increased HMG-CoA reductase activity by 1.3-fold at 32 mg/kg compared to the control group and did not significantly change that at 100 mg/kg (Fig. 3B) . Treatment of hamsters with pravastatin increased hepatic HMG-CoA reductase activity with a bell-shaped dose-response curve (Fig. 3D) Fig. 4 . FR194738 increased hepatic free cholesterol content by 14% at 32 mg/kg (Fig.  4B) , whereas total cholesterol content and cholesteryl ester content was not significantly changed up to 100 mg/kg (Figs.  4A, C) . Pravastatin increased total hepatic cholesterol content (Fig. 4D) , resulting from increases in both free cholesterol and cholesteryl ester content (Figs. 4E, F) . The effects were dose-dependent and leveled off at 32-100 mg/kg. The increase in hepatic content of total cholesterol, free cholesterol and cholesteryl ester were 75, 75 and 72%, respectively, at 32 mg/kg.
DISCUSSION
The most important finding in the present study is that dosing of FR194738, an inhibitor of squalene epoxidase, as a diet mixture for 10 d dose-dependently decreased serum cholesterol levels in hamsters, whereas pravastatin, an inhibitor of HMG-CoA reductase, increased them with a bell-shaped dose-response curve. Similar results were observed after oral daily administration, except for pravastatin at 100 mg/kg. Two out of 5 animals died at this dose, which suggests drug toxicity. These results clearly differentiate FR194738 and pravastatin, and indicate that attenuated cholesterol synthesis through different mechanisms causes different changes in serum cholesterol levels in hamsters.
The above-mentioned results for pravastatin coincide with the previous finding that the HMG-CoA reductase inhibitor lovastatin increased serum cholesterol levels in hamsters. 20) In contrast, Ma et al. 21) reported that lovastatin decreased serum cholesterol levels in hamsters. One explanation could be the duration of drug treatment: the former observed an increase at 6 d of treatment, while the latter paper observed a decrease at more than 10 d of treatment. It is also considered possible that inhibition of cholesterol synthesis triggers two opposite mechanisms; one being hypocholesterolemic and the other being hypercholesterolemic. It has been widely accepted that inhibition of HMG-CoA reductase up-regulates low density lipoprotein (LDL) receptors, enhances cholesterol uptake by the liver, and results in hypocholesterolemia. 5, 22) On the other hand, Brown and Goldstein 8) have postulated that expression of HMG-CoA reductase undergoes negative feedback control by metabolites which are produced in the cholesterol synthetic pathway downstream of HMG-CoA reductase. Thus, inhibition of HMG-CoA reductase induces HMG-CoA reductase expression and enhances de novo synthesis of cholesterol.
23) The newly synthesized cholesterol is then assembled into HDL in the liver and secreted from the liver, 24, 25) which leads to hypercholesterolemia. The present study demonstrated that pravastatin enhanced hepatic HMG-CoA reductase activity and the dose-response curve coincides with that for serum HDL cholesterol levels; both showed the maximal increase at 3.2-10 mg/kg. These results suggest that enhanced cholesterol synthesis and subsequent cholesterol secretion by means of HDL play an important part in pravastatin-induced hypercholesterolemia. On the other hand, the hepatic cholesterol content dose-dependently increased and leveled off at 32-100 mg/kg. These changes, at least those at high doses of pravastatin, can not be ascribed to enhanced cholesterol synthesis, since hepatic HMG-CoA reductase activity revealed a bell-shaped doseresponse curve. Furthermore, it has been reported that cholesterol catabolism to bile acid and cholesterol excretion into bile is not decreased by pravastatin. 26) We thus speculate that enhanced cholesterol uptake plays the major role in enhancement of hepatic cholesterol content. The widely accepted LDL receptor up-regulation by pravastatin 22) could be a contributing factor.
FR194738 slightly increased hepatic HMG-CoA reductase activity at 32 mg/kg, suggesting that inhibition of squalene epoxidase also causes HMG-CoA reductase induction. The degree of the change is less than that caused by pravastatin. Different mechanisms appear to be involved in the changes caused by FR194738 and pravastatin. It has been shown that sterols and non-sterol metabolites control the expression of HMG-CoA reductase at the transcriptional level 27) and at the post-transcriptional level, 28, 29) respectively. Furthermore, squalene epoxidase is located downstream in the cholesterol synthetic pathway, past the branch point for the biosynthesis of non-sterol products, while HMG-CoA reductase is located before the branch point. As a consequence, pravastatin inhibits the production of both sterols and non-sterol metabolites, 30) whereas FR194738 inhibits the production of sterols but not that of non-sterol metabolites. 11) This difference no doubt contributes to the lower degree of enhancement of HMG-CoA reductase activity by FR194738 compared to pravastatin.
FR194738 slightly but significantly increased hepatic cholesterol content at 32 mg/kg, and the dose-response curve parallels that of hepatic HMG-CoA reductase activity. These results may suggest that an enhancement of cholesterol synthesis is responsible for the change in the hepatic cholesterol content. However, induction of HMG-CoA reductase may be counteracted by the inhibitory effect of FR194738 on squalene epoxidase which is located downstream of HMG-CoA reductase, and the overall effect of FR194738 on the cholesterol synthesis could be less than that indicated by the enzyme activity. In turn, it has been demonstrated that cholesterol regulates squalene epoxidase expression and that inhibition of cholesterol synthesis by NB598, a squalene epoxidase inhibitor, causes an increase in the enzyme. 31) Thus, up-regulation of squalene epoxidase could be responsible for the increased hepatic cholesterol content. However, we did not determine the squalene epoxidase activity in the present study, and further studies are needed to clarify this point. Another possibility is enhanced hepatic cholesterol uptake by the liver. In this respect, it is interesting to note that NB-598 upregulates hepatic LDL receptor and decreases serum cholesterol levels. 32) In the present study, FR194738 decreased both serum HDL cholesterol and non HDL cholesterol levels. Hepatic cholesterol uptake by LDL receptors no doubt underlies the changes because LDL receptors recognize apoE as well as apoB, 33, 34) and that, LDL and HDL in hamsters contain apoB and apoE, respectively. 35) Although the larger dose of FR194738 (100 mg/kg) did not significantly increase hepatic cholesterol content, we speculate that the inhibitory activity of the dose on cholesterol synthesis might have overcome the enhancement of cholesterol uptake.
FR194738 decreased serum triglyceride levels moderately, while pravastatin markedly decreased serum triglyceride levels. As discussed above, hepatic uptake of LDL is considered to be enhanced by FR194738 and pravastatin. This no doubt leads to enhanced uptake of triglyceride by the liver and results in decreased serum triglyceride levels, because LDL contains triglyceride. On the other hand, Amin et al. 20) has reported that lovastatin decreases serum triglyceride levels and mevalonate supplement to the diet prevents these changes by lovastatin. As mevalonate is produced by HMGCoA reductase, its production is inhibited by HMG-CoA reductase inhibitors but not by FR194738. The different effects of pravastatin and FR194738 on mevalonate synthesis could be a contributing factor to the different degree of hypotriglyceridemia.
FR194738 was well tolerated up to 100 mg/kg. In contrast, pravastatin caused marked dose-dependent adverse effects. The toxicity of pravastatin seen in our study is comparable to that described with simvastatin in hamsters.
36) The elevations in serum GOT and GPT with simvastatin treatment in hamsters are fully prevented by coadministration of mevalonate, 36) suggesting that this is a mechanism-based effect linked to a blockade of mevalonate production, but not attributable to an intrinsic toxic property of the molecule itself.
Although the present study focused on the changes in the blood and liver, further studies are needed to clarify the following possibility. FR194738 and pravastatin may affect cholesterol synthesis in the peripheral tissues as well as in the liver, and the serum cholesterol levels may reflect changes in the cholesterol metabolism of peripheral tissues 37) It has been reported that extra-hepatic tissues account for 90% of whole animal sterol synthesis, 38) and that HDL plays an important role in removing cholesterol from the extra-hepatic tissues. 39) The same could be said with respect to triglyceride.
